A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Happy Bob App Integrates With Dexcom CGM to Provide a Playful Way to Engage With Real-Time Glucose Values and Improve Overall Self-Care

Through Dexcom’s real-time APIs, Happy Bob users can view their glucose values by quickly glancing at their Apple Watch or iPhone widget, create groups for support, collect stars and receive time-sensitive information and push notifications. Users can also see their historical data in the app for longer than 24 hours, access the expanded view, see insights on their desktop, and laugh at the in-app personalized messaging. Created by and for people with diabetes, Team Happy Bob has developed an app that alleviates the stress of daily management and glycemic control.

“Dexcom’s new Partner Web APIs opens the door for the future of connected devices. We are really excited to be one of their first collaborators and look forward to Dexcom users experiencing Happy Bob’s playful interface and ease of use. Diabetes exacts a huge mental toll and our app is designed to alleviate the data overload involved with daily care and glycemic control. Happy Bob is here to make your day better, and this partnership with Dexcom makes Happy Bob better able to do that,” says Jutta Haaramo, CEO at Harald AI.

Initially released in 2019, Happy Bob App quickly became popular with CGM users, who appreciated the personalized messages and gamification it offered. Embracing a lighter side to diabetes management was a game-changer in the digital data space and as a result, users were instantly more engaged and motivated to care for their health.

“Diabetes management is not a one-size-fits-all model, which is why we have always prioritized making our CGM data accessible to users in the platform of their choice,” said Jake Leach, executive vice president and chief technology officer at Dexcom. “We are excited to introduce Happy Bob as the latest partner to leverage our real-time APIs, which helps enable a more personalized and connected approach to continuous glucose monitoring.”

The Happy Bob App is available for download from the Apple App Store and Google Play Store for Dexcom CGM users in the U.S.

SourceHarald AI
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Sachita Shah, Sr. Director, Global Health, Butterfly Network, "Butterfly is proud to continue improving maternal health equity through Phase Two of the largest-scale handheld ultrasound distribution and training ever conducted in Sub-Saharan Africa. South Africa is an emerging market that continues to have disproportionately high rates of maternal mortality and stillbirth. Patients need easier access to antenatal imaging, and clinicians need better capabilities for screening high-risk conditions that lead to disproportionately worse pregnancy outcomes in rural areas in the public sector. Together with CHAI and GUSI, we can tackle this by making ultrasound much more accessible, so high-risk conditions can be identified earlier in care, which is known to improve outcomes.”
The clinical Study will enroll up to 97 patients at up to 12 European investigational sites. Completion of the study is expected this year, and results will support CE mark and pre-market approval submissions reports Vivasure Medical.
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.

By using this website you agree to accept Medical Device News Magazine Privacy Policy